牛牛AI助手已提取核心信息
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 50,000 shares of the company's common stock. The transaction, scheduled for January 29, 2024, is valued at approximately $3,025,570. The shares to be sold were acquired on the same day through the exercise of stock options, with the securities originating from the issuer and purchased with cash. This sale follows a previous transaction in the past three months where Kulkarni sold 20,000 shares, garnering total gross proceeds of $1,250,056.
CRISPR Therapeutics executive Samarth Kulkarni, who serves as both an officer and director, is set to sell 50,000 shares of the company's common stock. The transaction, scheduled for January 29, 2024, is valued at approximately $3,025,570. The shares to be sold were acquired on the same day through the exercise of stock options, with the securities originating from the issuer and purchased with cash. This sale follows a previous transaction in the past three months where Kulkarni sold 20,000 shares, garnering total gross proceeds of $1,250,056.
同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼将出售该公司的5万股普通股。该交易定于2024年1月29日进行，价值约为3,025,570美元。拟出售的股票在同一天通过行使股票期权收购，证券来自发行人并以现金购买。此次出售是在过去三个月中进行的一笔交易之后进行的，当时库尔卡尼出售了20,000股股票，总收益为1,250,056美元。
同时担任高管兼董事的CRISPR Therapeutics高管萨玛斯·库尔卡尼将出售该公司的5万股普通股。该交易定于2024年1月29日进行，价值约为3,025,570美元。拟出售的股票在同一天通过行使股票期权收购，证券来自发行人并以现金购买。此次出售是在过去三个月中进行的一笔交易之后进行的，当时库尔卡尼出售了20,000股股票，总收益为1,250,056美元。
有用
没用